|
 |
AbciximabThis page contains recent news articles, when available, and an overview of Abciximab but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Overview: Abciximab (when available) Used for the treatment of myocardial infarction and the prevention of platelet aggregation. Abciximab inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive molecules to GPIIb/IIIa receptor sites on activated platelets. For treatment of myocardial infarction, adjunct to percutaneous coronory intervention, unstable angina Mechanism Of Action: Abciximab binds to the intact platelet GPIIb/IIIa receptor, which is a member of the integrin family of adhesion receptors and the major platelet surface receptor involved in platelet aggregation. This binding is thought to involve steric hindrance and/or conformational alterations which block access of large molecules to the receptor rather than direct interaction with the RGD (arginine-glycine-aspartic acid) binding site of GPlIb/IIIa. News Articles on Abciximab BRAVE-3 Questions Value of Abciximab in PCI for Heart Attack - Mar 30, 2008 The BRAVE-3 study is the first to test the influence of high-dose clopidogrel on the value of abciximab exclusively in patients with ST-elevation myocardial FOXBusiness Tirofiban Is as Effective as Abciximab for Lowering ST-Segment ... - Apr 2, 2008 By Bruce Sylvester CHICAGO -- April 2, 2008 -- Treatment with tirofiban resulted in noninferior ST-segment resolution compared with abciximab among patients DG News Abciximab Fails to Add Benefit in Acute Myocardial Infarction for ... - Apr 1, 2008 By Ed Susman CHICAGO -- April 1, 2008 -- Researchers suggested that abciximab or other glycoprotein IIB/IIIA inhibitors are unnecessary if patients with DG News High-dose tirofiban as effective as abciximab in reducing ST ... - Mar 31, 2008 At least 50 percent recovery from ST-elevation occurred in 85.3 percent and 83.6 percent of patients in the tirofiban and abciximab groups, EurekAlert (press release), ACC: Both Tirofiban and Abciximab Work - Mar 30, 2008 By Peggy Peck, Executive Editor, MedPage Today CHICAGO, March 30 -- High-dose bolus tirofiban (Aggrastat) was as effective as abciximab (ReoPro) infusion in MedPage Today, Medicure Comments on Positive AGGRASTAT Results Presented at the ... - Apr 3, 2008 7.5% (p equals 0.55) between tirofiban and abciximab. The 984-patient ON-TIME 2 study showed that treatment with tirofiban in addition to aspirin, CNNMoney.com Drug-Eluting Stents Outperform Bare Stents in Heart Attack - Mar 30, 2008 ..."These findings may provide a robust scientific rationale for high-dose tirofiban as an alternative to abciximab in patients with STEMI," said Marco FOXBusiness An update from the American College of Cardiology 2008 Scientific ... - Apr 16, 2008 The first, the Comparison of Angioplasty With Infusion of Tirofiban or Abciximab and With Implantation of Sirolimus-Eluting or Uncoated Stents for the TheHeart.Org, Comparison Of Anticoagulants For Angioplasty Show Similar Outcomes - Mar 30, 2008 30, 2008) — In a comparison of anticoagulants and stents for use with angioplasty following a heart attack, the anticoagulants abciximab and tirofiban had Science Daily (press release) Anticoagulant Drugs Had Similar Outcomes After Angioplasty - Mar 30, 2008 SUNDAY, March 30 (HealthDay News) -- In heart attack patients who had angioplasty, the anticoagulant drugs abciximab and tirofiban produced similar outcomes U.S. News & World Report, Tirofiban in STEMI: Two new randomized clinical trials demonstrate ... - Apr 11, 2008 Complimentary strategies for reducing MACE in patients undergoing PCI for STEMI include abciximab infusion and uncoated stent implantation. TheHeart.Org, BRAVE-3: Drop GP IIb/IIIa inhibitors in STEMI - Mar 30, 2008 Chicago, IL - Use of the GP IIb/IIIa inhibitor abciximab in acute ST-elevation MI (STEMI) patients undergoing PCI after pretreatment with a loading dose of TheHeart.Org, MULTISTRATEGY: Tirofiban and sirolimus stents in primary PCI - Mar 30, 2008 Chicago, IL - High-dose tirofiban was "noninferior" to abciximab in terms of resolution of ST-segment elevation at 90 minutes in STEMI patients undergoing TheHeart.Org, Drug-Releasing Stent Better Than Uncoated Stent For Angioplasty - Mar 30, 2008 The researchers were interested in testing if using tirofiban instead of abciximab could results in similar benefits as well as clinical and economic Medical News Today, Tirofiban can be used to treat STEMI, study shows - Apr 1, 2008 High doses of the drug tirofiban is as effective as abciximab in reducing ST-segment elevation in patients with ST-elevation myocardial infarction (STEMI), Nursing Times, Encouraging News and Discoveries in the Use of Drug-Eluting Stents - Apr 10, 2008 Dr. Valgimgli and associates studied patients who received anticoagulants Abciximab and Tirofiban within 90 minutes of angioplasty procedure. DOTmed.com (press release), ACC: Drug-Eluting Stent Safety for Acute MI Seen in Real World ... - Mar 31, 2008 ...improved major cardiovascular adverse events over abciximab (ReoPro) and heparin (See: HORIZONS AMI Verdict: Bivalirudin (Angiomax) a Winner). MedPage Today, ACC: Manual Clot Removal Boosts Clinical Benefit of PCI in Acute MI - Mar 30, 2008 All patients got standard treatment with heparin, aspirin, a 600-mg loading dose of clopidogrel (Plavix), and abciximab (ReoPro). MedPage Today, Early PCI outcomes comparable with eptifibatide and abciximab - Feb 21, 2008 A pooled analysis of data from previous trials has suggested that survival may be improved when patients are treated with abciximab. Whether eptifibatide Medicexchange, Which IIb/IIIa blocker for primary PCI? - Feb 27, 2008 Ann Arbor, MI - Despite there being more data on the use of abciximab than other GP IIb/IIIa blockers in primary PCI patients, eptifibatide appears to be TheHeart.Org, CARESS-in-AMI published: PCI transfer best for STEMI patients ... - Feb 14, 2008 The trial was conducted in France, Italy, and Poland and recruited 600 patients aged 75 years or younger, as the half-dose reteplase/abciximab regimen was TheHeart.Org, Thrombolytics safe, effective in cath-related stroke, says analysis - Feb 25, 2008 Still, Khatri told heartwire, tPA would be contraindicated in post-cath patients who had recently been given abciximab or anticoagulants, although treatment TheHeart.Org, Primary Percutaneous Coronary Intervention - Jan 23, 2008 2 , 3 Other studies have revealed decreased 30-day mortality and reinfarction rates with the use of the glycoprotein IIb/IIIa inhibitor abciximab. New England Journal of Medicine (subscription), A Bridge to Nowhere — The Troubled Trek of Foreign Medical Graduates - Jan 16, 2008 What meaning should such terms as angioplasty, abciximab, and door-to-balloon time have for this surgeon who always summoned a medical consultant at any New England Journal of Medicine (subscription), PCI complications fewer with radial rather than femoral approach - Dec 11, 2007 The patients were randomized to receive PCI via the radial or femoral approach, and were treated with the platelet aggregation inhibitor abciximab. Medicexchange, Focus on antiplatelet therapy: An update from AHA 2007 - Dec 7, 2007 Schulz S, Schomig A, Kastrati A. Correlates of bleeding after a 600 mg loading dose of clopidogrel, with and without abciximab: a pooled analysis of 4 TheHeart.Org, EVA-AMI: Eptifibatide equal to abciximab for STEMI patients ... - Nov 4, 2007 Orlando, FL - Eptifibatide (Integrilin, Millennium Pharmaceuticals) given as a double bolus was just as effective as abciximab (reopro, Eli Lilly/Centocor) TheHeart.Org, AHA: Glycoprotein iib/iiia Drugs Come Out Even for PCI - Nov 5, 2007 Point out to interested patients that abciximab is FDA approved as an adjunct to PCI, and eptifibatide is approved for treatment of patients with acute MedPage Today, TCT: Bivalirudin (Angiomax) Effective in Primary PCI for STEMI - Oct 24, 2007 The direct thrombin inhibitor was compared with a standard anti-coagulation therapy of a glycoprotein iib/iiia inhibitor (abciximab) plus unfractionated MedPage Today, HORIZONS AMI Verdict: Bivalirudin (Angiomax) a Winner - Oct 24, 2007 Moreover, the drug was associated with a 40% reduction in major bleeding events compared the abciximab/heparin regimen. Dr. Stone reported results of the MedPage Today, Big rise in hospital drug costs - Oct 30, 2007 ...prescribing costs were rising faster was because many of the newer costlier drugs appraised by NICE were only used in a hospital setting (eg, abciximab). OnMedica, New Anti-Clotting Drug Shows Promise in Heart Patients - Nov 4, 2007 Another trial found that Integrilin (eptifibatide) was as effective as reopro (abciximab) in restoring blood flow to the heart in patients undergoing PCI. Washington Post, Is bivalirudin now the antithrombotic of choice in primary PCI? - Nov 1, 2007 Remember that this was the situation moving from EPIC to EPILOG with abciximab. Lowering UFH dose not only translated into less bleeding but also better TheHeart.Org, Daiichi Sankyo, Lilly Announce New Prasugrel Head-to-Head Phase ... - Nov 4, 2007 Building on the strong foundation of reopro(R) (abciximab), Lilly is in the process of building a robust cardiovascular pipeline. CNNMoney.com Daiichi Sankyo, Lilly Announce New Prasugrel Head-to-Head Phase ... - Nov 4, 2007 Building on the strong foundation ofreopro(R) (abciximab), Lilly is in the process of building a robustcardiovascular pipeline. Juraforum.de, HORIZONS AMI: Bivalirudin reduces bleeding, adverse clinical ... - Oct 24, 2007 ...plus a GP iib/iiia inhibitor (abciximab or eptifibatide), or to bivalirudin monotherapy (0.75 mg/kg bolus; infusion 1.75 mg/kg per hour), stopped at the TheHeart.Org, Women at Greater Risk After Fibrinolytic Treatment in MI - Oct 23, 2007 In the current analysis, the investigators studied MI patients randomized to standard-dose reteplase (Retavase) or standard dose abciximab (reopro) plus MedPage Today, Potential New Way Of Treating Inflammatory Diseases Identified - Sep 18, 2007 Kettritz and colleagues tested three of these drugs -- abciximab, epifibatide, and tirofiban -- on cell cultures in which neutrophils had received the Science Daily (press release) A promising R&D portfolio, well positioned to deliver future growth - Sep 17, 2007 ...demonstrated good safety with a bleeding rate similar to unfractionated heparins with or without abciximab and with no induced thrombocytopenia. Newsdesk, FINESSE: Abciximab-only- and lytic/abciximab-facilitated PCI no ... - Sep 3, 2007 Vienna, Austria - The long-awaited results from the FINESSE trial should put to rest once and for all the idea that using a half-dose lytic plus abciximab, TheHeart.Org, Triple antiplatelet therapy found excessive at interventions for ... - Sep 3, 2007 Vienna, Austria - Adding abciximab (ReoPro, Lilly) to standard adjuvant double-antiplatelet therapy may help prevent reocclusion after interventional TheHeart.Org, Immediate emergency angioplasty can save the lives of those ... - Sep 3, 2007 Abciximab facilitates the rate and extent of thrombolysis: results of the thrombolysis in myocardial infarction (TIMI) 14 trial. Circulation 1999;99:2720-32 News-Medical.net, CARESS: PCI after lysis beneficial? - Sep 3, 2007 Vienna, Austria - The CARESS trial has suggested that in patients undergoing lytic therapy with half-dose reteplase and abciximab, immediate transfer for TheHeart.Org, Medicure Inc.: Positive AGGRASTAT(R) Results Featured in the ... - Jul 11, 2007 CNNMoney.com...today announced that the two-year, follow-up results from the STRATEGY (Single High-Dose Bolus Tirofiban and Sirolimus-Eluting Stent Versus Abciximab Dade Behring Grants Sublicense to Beckman Coulter for the Use of ... - Jun 27, 2007 Genetic Engineering News (press release),It has also been proposed for the identification of patients who benefit from glycoprotein IIb/IIIa receptor antagonist ReoPro(R) (abciximab) therapy, Bivalirudin as Effective as Heparin in Acute Coronary Syndromes ... - May 14, 2007 DG NewsBivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: results of the Medicure's Aggrastatr Highlighted in Expert Opinion Journal - Apr 20, 2007 PharmaLive.com (press release),..."The available data suggests that high-dose bolus tirofiban may be as effective and safe as abciximab in patients undergoing PCI. Study Identifies Steps To Improve Safety Of Renal Artery Stenting - Apr 3, 2007 Science Daily (press release)Abciximab reduced the occurrence of platelet-rich emboli (particles or debris) in the EPD from 42 to seven percent. This difference was highly significant The Moose in the Room - Apr 16, 2007 Scientist,A significant part of this job was maintaining a strategic alliance with the then-independent Centocor to market the antithrombotic drug, ReoPro (abciximab) Kidney stent helps lower blood pressure - Mar 31, 2007 Toledo Blade,And a quarter received the stent, the filter, and the platelet drug, Abciximab. The research found that patients given both the drug and the filter with Effects of GP IIb/IIIa Inhibitors on Vascular Inflammation ... - Jan 17, 2007 HeartZine,Abciximab and the small-molecule GP IIb/IIIa inhibitors (eptifibatide, tirofiban) have separate, distinct binding sites on the GP IIb/IIIa receptor complex. Medicure Completes US$25.9 Million Private Placement - Dec 28, 2006 Genetic Engineering News (press release),The meta-analysis suggests that Single High-Dose Bolus tirofiban may be as effective as abciximab in patients undergoing PCI with a comparable safety Medicure Announces Second Quarter Fiscal 2007 Financial Results - Jan 12, 2007 PharmaLive.com (press release),The Company announced that new data comparing Single High-Dose Bolus AGGRASTATR (tirofiban) versus ReoProR (abciximab) in patients undergoing percutaneous Primary PCI for Myocardial Infarction with ST-Segment Elevation - Jan 3, 2007 New England Journal of Medicine (subscription),Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction: a randomized trial. JAMA 2005;293:2109-2117. Abciximab Helpful in Thrombosis During Intracranial Aneurysm ... - Dec 4, 2006 DG NewsIn what is believed to be the largest case series evaluation of the use of abciximab in this setting, researchers found that use of the drug was associated Abciximab reduces risk of adverse events for patients with acute ... Oct 11, 2006 ...a procedure such as balloon angioplasty or stent placement had a reduced risk of adverse events if they received the anti-clotting drug Abciximab ( ReoPro ). ... -Xagena.it, Medicure Announces New Aggrastat'R' Data to be Presented at 2006 ... Nov 6, 2006 ...that an abstract outlining a recently completed meta-analysis comparing Single High-Dose Bolus AGGRASTAT ® (tirofiban) and ReoPro ® (abciximab) in patients ... -CCNMatthews (press release), Medicure Announces New Aggrastat Data to Be Presented at 2006 ... Nov 6, 2006 ...that an abstract outlining a recently completed meta-analysis comparing Single High-Dose Bolus AGGRASTATR (tirofiban) and ReoProR (abciximab) in patients ... -PharmaLive.com (press release), GP IIb/IIIa inhibition: Time to drop the infusion? Oct 11, 2006 ...whereas in the GP IIb/IIIa arm, they gave the FDA-approved dose: they ran [abciximab or eptifibatide] for 12 to 24 hours, because that's what's in the package ... -TheHeart.Org, HAAMU-STENT: Less late loss in STEMI patients treated with drug ... Oct 27, 2006 2006 meeting. Patients were part of the larger HAAMU trial that compared abciximab-facilitated PCI with thrombolysis. "It seems ... -TheHeart.Org, TCT: One-Year Data Confirm Benefit of Stem Cell Therapy After MI Oct 26, 2006 REPAIR-AMI was supported by a grant from Guidant, which also provided the balloon catheters. Eli Lilly supplied ReoPro (abciximab). ... -MedPage Today, Fondaparinux in Patients With ST-Segment Elevation Myocardial ... Oct 31, 2006 Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial ... -Journal of American Medical Association (subscription), Roadmap To Integrin Activation Created By UCSD Researchers Sep 21, 2006 Direct inhibitors of GPIIb-IIIa binding include antithrombotics such as eptifibatide (Integrelin), abciximab (Reopro), and tirofiban (Aggrestat), drugs that ... -Medical News Today Benefit Seen for Bone Marrow Treatment Following Heart Attack Sep 20, 2006 REPAIR-AMI was supported by a grant from Guidant, which also provided the balloon catheters. Eli Lilly supplied ReoPro (abciximab). ... -MedPage Today VIAMI: Post-thrombolytic PCI guided by viability testing cuts ... Sep 5, 2006 ...recurrent ischemia. Percutaneous intervention consisted of coronary stenting accompanied by the antiplatelet agent abciximab. The ... -TheHeart.Org New Trials of Antithrombotic Therapy for ACS -- ACC 2006 Jul 21, 2006 The patients were then randomized to receive abciximab at the standard dosing vs placebo, and the primary endpoint looked at death, MI, or urgent ... -Medscape (subscription) Similar Early Outcomes With Eptifibatide and Abciximab Before ... 16 May 2006 CHICAGO, IL -- May 15, 2006 -- The glycoprotein IIb/IIIa inhibitors abciximab and eptifibatide appear to be equally effective in improving in-hospital outcomes ... - DG News Mechanisms Behind Rare Clotting Disorder Exposed Apr 21, 2006 In addition, this receptor is also the target for several anti-platelet agents, such as ReoPro (abciximab), a monoclonal antibody that inhibits platelet ... - MedPage Today Brand Names/Synonyms: Abciximab is also known by the following brand names and/or synonymsReoPro; 7E3 antibody; antiGPIIBIIIa; ReoPro (Centocor) Drug Category: Abciximab is categorized under the following by the FDA: Anticoagulants; Antiplatelet Agents Dosage Forms: Not Available Absorption: Not Available Interactions: Not Available Chemical IUPAC Name: Chimeric human-murine (anti CD41) 7E3 antibody. : |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines mongabay.com
COPYRIGHT 2007 MONGABAY.COM |